GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allenex AB (LTS:0O9J) » Definitions » YoY EBITDA Growth

Allenex AB (LTS:0O9J) YoY EBITDA Growth : -50.00% (As of Mar. 2016)


View and export this data going back to . Start your Free Trial

What is Allenex AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Allenex AB's YoY EBITDA Growth for the quarter that ended in Mar. 2016 was -50.00%.

Allenex AB's EBITDA per Share for the three months ended in Mar. 2016 was £0.00.


Allenex AB YoY EBITDA Growth Historical Data

The historical data trend for Allenex AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allenex AB YoY EBITDA Growth Chart

Allenex AB Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -225.00 106.84 12.50 100.00 -

Allenex AB Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 50.00 -33.33 -33.33 -50.00

Allenex AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Allenex AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2015 is calculated as:

YoY EBITDA Growth (A: Dec. 2015 )
=(EBITDA per Share (A: Dec. 2015 )-EBITDA per Share (A: Dec. 2014 ))/ | EBITDA per Share (A: Dec. 2014 ) |
=(0.018-0.018)/ | 0.018 |
=0.00 %

Allenex AB's YoY EBITDA Growth for the quarter that ended in Mar. 2016 is calculated as:

YoY EBITDA Growth (Q: Mar. 2016 )
=(EBITDA per Share (Q: Mar. 2016 )-EBITDA per Share (Q: Mar. 2015 )) / | EBITDA per Share (Q: Mar. 2015 )) |
=(0.002-0.004)/ | 0.004 |
=-50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allenex AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Allenex AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Allenex AB (LTS:0O9J) Business Description

Traded in Other Exchanges
N/A
Address
Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.

Allenex AB (LTS:0O9J) Headlines

No Headlines